Ergoteles’s 9 Meters Biopharma NMTR Stock Holding History

Ergoteles’s Portfolio NMTR Stock Details NMTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-45,573	Closed	-$196K	–	2066
2022 Q3	$196K	Sell	45,573 -4,237	-9%	-$21K	0.01%	1194
2022 Q2	$260K	Buy	+49,810	New	+$469K	0.01%	1186

Other funds holding NMTR

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

ODFS

O'Donnell Financial Services San Rafael, California $290M AUM 15.6% 1-Year Est. Return

Ergoteles's NMTR Position: Q4 2022 in Review

Ergoteles sold out of 9 Meters Biopharma (NMTR) in Q4 2022, closing a stake of 45,573 shares — an estimated $196K sold.

Ergoteles first reported a position in NMTR in Q2 2022 and held it in 2 quarters. The position peaked at $260K in Q2 2022. 42 funds tracked by Wall St. Rank hold NMTR as of Q4 2022.

Ergoteles reported no remaining 9 Meters Biopharma position as of Q4 2022 after selling out during the quarter.
Ergoteles sold 45,573 9 Meters Biopharma shares in Q4 2022, an estimated $196K.
Ergoteles first reported a position in 9 Meters Biopharma in Q2 2022 and held it in 2 quarters.
Ergoteles's 9 Meters Biopharma position peaked at $260K in Q2 2022.
42 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q4 2022.

Based on Ergoteles's 13F filing for Q4 2022, filed 14 Feb 2023.